A reanalysis of a major cardiovascular trial has found that semaglutide, the widely used metabolic drug, appears to slow the worsening of blood-based markers associated with future dementia risk in older adults — a finding that places the molecule at an unexpected crossroads between heart health and brain aging. The discovery does not prove that the drug prevents dementia, but it opens a corridor of inquiry into whether the metabolic and inflammatory pathways semaglutide influences may also quietly shape the mind's long-term fate. Science here is doing what it often must: reading shadows on a